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Classification) group of drugs was prescribed. Our composite health index, CHI, 
is a coverage-weighted average of the separate indices we construct for persons 
covered by each community drug scheme in each region. Results: Respiratory 
health status varies most across Irish regions but Cardiovascular, Central Nervous 
System and ‘Other’ health conditions have higher CHI weights and contribute more 
to overall regional health disparities. The Midlands region had the poorest health 
status in 2010 (8% below the national average); the Eastern region had the best 
(6% above average), followed closely by the Mid-West. The Mid-West has a better 
health status than the Midlands despite having lower income and a larger elderly 
population share. The health status of the Eastern region is just 2% higher than the 
Mid-West even though its income is 6% higher and the percentage of its population 
aged over 65 is 1.8 percentage points lower. Simple economic and demographic 
variables - mean income and the elderly population share – correlate well with 
health status. ConClusions: Our index maps significant regional disparities and 
paves the way for complementary epidemiological studies to trace their underlying 
lifestyle and medical causes and inform regional health policy.
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objeCtives: Potentially inappropriate medicines (PIMs) can result in increased 
morbidity, adverse drug events and hospitalizations. Polypharmacy is the strongest 
predictor of PIMs,the prevalence of which was 36% in 2007 in those aged ≥ 70 years 
, with an associated expenditure of over € 45 million. Medicines review may have 
the potential to improve patient outcomes and reduce prescribing costs. This study 
aims to assess the feasibility of introducing medicines review to reduce PIMs in older 
patients. Methods: OPTI-SCRIPT is a cluster randomized controlled trial (RCT), that 
aims to assess the effectiveness of a complex intervention incorporating academic 
detailing, a medicines review with web-based pharmaceutical treatment algorithms 
that provide recommended alternative treatments, and tailored patient information 
leaflets in reducing PIMs. A qualitative evaluation is being conducted to determine the 
feasibility and acceptability of the intervention. Results: Twenty-one GP practices 
(response rate 32.3%) participated. Identifying patients with a PIM required consider-
able time and expertise. Practices screened all patients aged ≥ 70 years to identify 
those suitable to participate. A pharmacist reviewed their repeat medications, identi-
fying patients with a PIM who were then invited to participate. Despite being offered 
a once off review of their current prescriptions with their GP, only 37.4% (196) agreed 
to participate. Preliminary qualitative findings indicate that intervention group GPs 
valued the review process as an opportunity to reflect on their prescribing practice. 
Some GPs highlighted that conducting routine structured reviews with older patients 
wouldn’t be feasible due to the time, resources and funding available to them cur-
rently in primary care. Participating patients placed a high value on their medicines 
review. ConClusions: Preliminary findings illustrate that implementing a system of 
structured reivews for older patients with a PIM is challenging. However, participating 
GPs and older patients saw the value of conducting medicines reviews, but formal 
resourcing of such services would need to be considered.
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objeCtives: The present study aimed to determine the proportion of physicians 
in Japan who use clinical practice guidelines, as well as factors influencing this 
choice. Methods: We conducted an on-line cross-sectional survey throughout 
Japan on general internists, gastroenterologists, cardiologists, endocrinologists and 
general surgeons, including gastrointestinal or breast surgeons, who registered for 
marketing research. Questions addressed their usage of CPGs in practice, education, 
and research, as well as their attitudes toward CPGs. We then investigated associa-
tions between usage and characteristics of the respondents. Results: We received 
responses from 1342 physicians, 1222 (91.1%) of whom were male (mean age (SD), 46.5 
(9.6) years). The proportion of respondents who always or often use CPGs in several 
practice settings, such as when providing explanations to patients based on CPGs, 
ranged from 27.7% to 54.6%. Among them, 822 respondents (61.3%) applied 1 to 4 CPGs, 
and 381 (28.4%) applied 5 to 9. Usage differed according to age group, subspecialty, 
and workplace. After multivariate adjustment, the mean probability (95% confidence 
interval) of a high usage of CPGs when providing explanations to patients was 65% 
(60% - 71%) and 40% (30% - 50%) for those aged < 40 y and ≥ 60 y, respectively, 44% 
(38% - 50%) for general internists, 65% (59% - 71%) for surgeons, and 51% (46% - 57%) 
and 65% (58% - 72%) for those working in clinics and university hospitals, respectively. 
Attitudes towards the trustworthiness and convenience of CPGs were associated 
with usage, although this was unable to explain all differences in usage among sub-
groups. ConClusions: A substantial proportion of Japanese physicians use CPGs 
in clinical practice. Age, subspecialty, and workplace were independently associated 
with CPG usage. This should be considered during the process of CPG implementation.
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objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all health care stakeholders, including clinical experts. In the past, clini-
the results did not cause an added value of the drug in this respective application. 
In seven cases the indirect comparison was declined due to a different comparator 
as determined by the G-BA. Three indirect comparisons were declined because of 
methodological deficiencies and another three indirect comparisons were declined 
because non-adjusted indirect comparisons were performed. ConClusions: The 
IQWiG only accepts adjusted indirect comparisons. The application of the correct 
methodology is necessary to gain valid results and shall not be questioned. The 
IQWiG approach is accurate with regard to contents and correct in a legal sense. 
However the procedure shows, that the external preconditions and methodologi-
cal requirements are demanding and almost impossible to fulfill. Main reason for 
denial is the divergence from the prespecified appropriate comparator set by the 
G-BA. To get back to the original aim of the early benefit assessment, a more realistic 
and reasonable determination of the appropriate comparator would be desirable.
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objeCtives: Policy makers of municipalities decided to adopt health technol-
ogy into the Brazilian Public Health System (SUS). This group met during national 
conferences. The last conference, “The XXVIII National Congress of Municipal 
Health Secretariats (CONASEMS)”, took place during June 11 to 14, 2012. The aim 
was describe the views of participants at the CONASEMS event regarding technol-
ogy assessment criteria for the Brazilian Public Health System (SUS). Methods: 
A survey applied at the Ministry of Health’s exhibition booth, June 11 to 14, 2012. 
Three variables were studied for the survey: “Participant Profile”, “Knowledge of 
Health Technology Assessment for Adoption by the SUS” and pre-selected criteria for 
assessing health technologies (where 1= most important and up to 9= least impor-
tant) Results: The survey encompassed 5.6% (244/4.328) of all conference partici-
pants. Of these, 43% represented policy makers; 35% health professionals and 22% 
others. Of the total amount of participants, 67% have little or average knowledge of 
HTA and 14% declared having no knowledge of the area. The values in the adoption 
of health technologies were ranked by delegates. The score of one was: evidence on 
patient safety, improved quality of life and patient survival, impact on the popula-
tion’s health. The score nine was: relationship between benefits and costs, health 
system costs and patient costs. ConClusions: Considering the results, the value 
related to criteria regarding quality of life and survival were the most important in 
detriment to cost criteria. It is important to involve the Brazilian Network for Health 
Technology Assessment (REBRATS) as an additional contribution to the application 
of the new Brazilian law regarding the incorporation of health technologies.
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objeCtives: Early benefit assessment pursuant to AMNOG was introduced to cut 
costs and illustrate the additional benefit of new pharmaceuticals including orphan 
drugs at launch in Germany. In this process orphan drugs have a special status. The 
EMA orphan drug designation implies the assumption that at least a not-quanti-
fiable additional benefit is set by law. However the extent of the additional benefit 
still has to be demonstrated by the manufacturer. Methods: By June 2013 seven 
orphan drug dossiers have been submitted and assessed. Only one product has been 
admitted an important additional benefit. Four substances had a minor additional 
benefit and two substances had a not-quantifiable additional benefit. Results: An 
additional benefit needs to be proven against a comparator. But the G-BA will not 
define an appropriate comparator as for non-orphan drugs. Instead, the assessment 
of orphan drugs is based on the pivotal trial; the comparator will be derived from 
this trial. Due to the early phase of pivotal trials in rare diseases, using a compara-
tor is not common. Furthermore, phase II trials often do not meet requirements in 
terms of evidence level requested: randomized controlled trials with large patient 
populations are unusual in orphan diseases as well as investigation of valid patient 
relevant endpoints or validated surrogate endpoints. ConClusions: The G-BA 
requirements for HTA assessments are drawn from phase III trials and demonstra-
tion of an additional benefit over an appropriate comparator, which also serves as 
price benchmark. The requirements derived for all newly launched products do not 
reflect orphan drug reality, which is indication and not agent based. In summary 
the EMA declaration of early admission of orphan drugs in phase II conflicts with 
the G-BA’s methodological requirements for the quantification of an additional 
benefit. In fact, manufacturers of orphan drugs face an additional barrier before 
launch in Germany.
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objeCtives: This paper constructs a composite index that is sufficiently compre-
hensive to rank the overall health status of Irish regions and sufficiently detailed to 
identify the principal sources of varying regional health status. Methods: We draw 
on the CSO (Central Statistics Office), PCRS (Primary Care Reimbursement Service) 
and IPH (Institute of Public Health) health and medicines databases to construct 
a composite index of the health status of the 8 HSE regions in Ireland in 2010. Our 
composite health index (CHI) has 6 component indices. Each maps the regional 
prevalence of major health conditions for which an ATC (Anatomical Therapeutic 
